Dare Bioscience, Inc. (NASDAQ: DARE), a health biotech company focused on women's health, announced its financial results for the year ended December 31, 2025, along with a business update. The company reported approximately $24.7 million in cash and cash equivalents as of December 31, 2025, and a working capital of approximately $3.4 million. During 2025, Dare received about $20.8 million in net proceeds from equity offerings and significant non-dilutive funding, including approximately $13.6 million from the Gates Foundation. The company highlighted its commercial launch of DARE to PLAY™ Sildenafil Cream, a topical treatment aimed at addressing women's sexual health issues, which is expected to begin generating revenue in Q2 2026. Additionally, Dare is advancing its pipeline with several products targeting various aspects of women's health, including DARE to RECLAIM™ and Ovaprene™, a non-hormonal contraceptive currently in Phase 3 clinical trials. The company is also preparing for a Phase 2 study of DARE-HPV, a therapeutic candidate for high-risk HPV infections. The leadership expressed confidence in the company's strategy and the potential for multiple catalysts in the near future, emphasizing their commitment to improving women's healthcare.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.